Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Tongue Neoplasms 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lymphoma 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Brenner Tumor 1Breast Neoplasms 1

Interventions

Paclitaxel 8Carboplatin 8Taxes 6Topotecan 3Cisplatin 3Bevacizumab 3SS1(dsFv)PE38 2Filgrastim 2Etoposide 2veliparib 1trioctyl phosphine oxide 1paclitaxel poliglumex 1VTX-2337 1Thiotepa 1Reverse Transcriptase Polymerase Chain Reaction 1Platinum 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Immunoglobulin G 1Granulocyte Colony-Stimulating Factor 1Docetaxel 1Disulfides 1Chemotherapy, Adjuvant 1Bortezomib 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Brenner Tumor × VTX-2337 × Clear all
NCT01294293 2014-12-25

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

GOG Foundation

Phase 1 Completed
20 enrolled
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡